Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > CYAD Celyad Oncology > Detailed Quotes

CYAD Celyad Oncology

1.380
-0.010-0.72%
Close 09/30 16:00 ET
High
1.380
Open
1.341
Turnover
4.36K
Low
1.240
Pre Close
1.390
Volume
3.29K
Market Cap
31.18M
P/E(TTM)
Loss
52wk High
5.320
Shares
22.59M
P/E(Static)
Loss
52wk Low
1.240
Float Cap
18.74M
Bid/Ask %
90.48%
Historical High
67.940
Shs Float
13.58M
Volume Ratio
0.40
Historical Low
1.240
Dividend TTM
--
Div Yield TTM
--
P/B
1.03
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.02%
Amplitude
10.06%
Avg Price
1.325
Lot Size
1
Float Cap
18.74M
Bid/Ask %
90.48%
Historical High
67.940
Shs Float
13.58M
Volume Ratio
0.40
Historical Low
1.240
Dividend TTM
--
P/B
1.03
Dividend LFY
--
Turnover Ratio
0.02%
Amplitude
10.06%
Avg Price
1.325
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
CEO: Mr. Filippo Petti
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...